Docking studies of some pyrazole containing compounds in the cyclooxygenase-2 active site
Doking studije nekih jedinjenja sa pirazolom u aktivnom mestu ciklooksigenaze-2
Article (Published version)
Metadata
Show full item recordAbstract
Whereas nonselective nonsteroidal anti-inflammatory drugs, such as aspirin, ibuprofen and
diclofenac, inhibit both cyclooxygenase-1 and cyclooxigenase-2 enzymes, selective inhibitors
target cyclooxygenase-2, which is overexpressed in inflammation, but also in cancer,
atherosclerosis, Alzheimer's disease, and Parkinson`s disease. Potential cardiovascular and
hepatic side effects of cyclooxygenase-2 inhibitors have limited their use. The development of
selective and safe cyclooxygenase-2 inhibitors remains a high priority in drug discovery. Based
on the structure of previously investigated newly synthesized β-hydroxy-β-arylpropanoic acids,
two groups of compounds were designed: analogs in which one of the benzene rings was replaced
by a pyrazole, while the carboxyl group was retained, and amides of β-hydroxy-β-arylpropanoic
acids with pyrazole. The compounds were docked into the 3D structure of the catalytic site of the
enzyme cyclooxygenase-2 using AutoDock Vina 1.2.0. and the... obtained interactions were
compared with the interactions of celecoxib, a selective inhibitor. The amides had lower binding
energies than the designed acids, which makes them attractive target compounds for synthesis
and further examination.
Neselektivni nesteroidni antiinflamatorni lekovi poput aspirina, ibuprofena i diklofenaka
inhibiraju enzime ciklooksigenazu-1 i ciklooksigenazu-2, a selektivni inhibitori ciljaju
ciklooksigenazu-2 koja je prekomerno izražena u inflamaciji, ali takođe i kod kancera,
ateroskleroze, Parkinsonove i Alchajmerove bolesti. Potencijalni kardiovaskularni i hepatički
neželjeni efekti selektivnih inhibitora ciklooksigenaze-2 su ograničili njihovu primenu. Razvoj
selektivnih i bezbednih inhibitora ciklooksigenaze-2 ostaje veoma prioritetna oblast u otkrivanju
lekova. Na osnovu strukture prethodno istraživanih novosintetisanih β-hidroksi-β-arilpropanskih
kiselina dizajnirane su dve grupe jedinjenja: analozi u kojima je jedan od benzenovih prstenova
zamenjen pirazolom, uz zadržavanje karboksilne grupe, i amidi β-hidroksi-β-arilpropanskih
kiselina sa pirazolom. Program AutoDock Vina 1.2.0 je korišćen za dokovanje dizajniranih
jedinjenja u 3D strukturu katalitičkog mesta enzima ciklooksigena...ze-2, a ostvarene interakcije su
upoređene sa interakcijama koje ostvaruje selektivni inhibitor celekoksib. Amidi su imali nižu
energiju vezivanja od kiselina, što ih čini dobrim kandidatima za sintezu.
Keywords:
cyclooxygenase-2 inhibitors / molecular interactions / rational drug design / protein-ligand interactions / β-hydroxy-β-arylpropanoic acids / ciklooksigenaza-2 / molekularne interakcije / racionalno dizajniranje lekova / protein-ligand interakcije / β-hidroksi-β-arilpropanske kiselineSource:
Arhiv za farmaciju, 2023, 73, 3, 205-215Publisher:
- Savez farmaceutskih udruženja Srbije (SFUS)
Funding / projects:
Institution/Community
PharmacyTY - JOUR AU - Savić, Jelena AU - Antonijević, Marija AU - Crevar, Milkica AU - Brborić, Jasmina PY - 2023 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4978 AB - Whereas nonselective nonsteroidal anti-inflammatory drugs, such as aspirin, ibuprofen and diclofenac, inhibit both cyclooxygenase-1 and cyclooxigenase-2 enzymes, selective inhibitors target cyclooxygenase-2, which is overexpressed in inflammation, but also in cancer, atherosclerosis, Alzheimer's disease, and Parkinson`s disease. Potential cardiovascular and hepatic side effects of cyclooxygenase-2 inhibitors have limited their use. The development of selective and safe cyclooxygenase-2 inhibitors remains a high priority in drug discovery. Based on the structure of previously investigated newly synthesized β-hydroxy-β-arylpropanoic acids, two groups of compounds were designed: analogs in which one of the benzene rings was replaced by a pyrazole, while the carboxyl group was retained, and amides of β-hydroxy-β-arylpropanoic acids with pyrazole. The compounds were docked into the 3D structure of the catalytic site of the enzyme cyclooxygenase-2 using AutoDock Vina 1.2.0. and the obtained interactions were compared with the interactions of celecoxib, a selective inhibitor. The amides had lower binding energies than the designed acids, which makes them attractive target compounds for synthesis and further examination. AB - Neselektivni nesteroidni antiinflamatorni lekovi poput aspirina, ibuprofena i diklofenaka inhibiraju enzime ciklooksigenazu-1 i ciklooksigenazu-2, a selektivni inhibitori ciljaju ciklooksigenazu-2 koja je prekomerno izražena u inflamaciji, ali takođe i kod kancera, ateroskleroze, Parkinsonove i Alchajmerove bolesti. Potencijalni kardiovaskularni i hepatički neželjeni efekti selektivnih inhibitora ciklooksigenaze-2 su ograničili njihovu primenu. Razvoj selektivnih i bezbednih inhibitora ciklooksigenaze-2 ostaje veoma prioritetna oblast u otkrivanju lekova. Na osnovu strukture prethodno istraživanih novosintetisanih β-hidroksi-β-arilpropanskih kiselina dizajnirane su dve grupe jedinjenja: analozi u kojima je jedan od benzenovih prstenova zamenjen pirazolom, uz zadržavanje karboksilne grupe, i amidi β-hidroksi-β-arilpropanskih kiselina sa pirazolom. Program AutoDock Vina 1.2.0 je korišćen za dokovanje dizajniranih jedinjenja u 3D strukturu katalitičkog mesta enzima ciklooksigenaze-2, a ostvarene interakcije su upoređene sa interakcijama koje ostvaruje selektivni inhibitor celekoksib. Amidi su imali nižu energiju vezivanja od kiselina, što ih čini dobrim kandidatima za sintezu. PB - Savez farmaceutskih udruženja Srbije (SFUS) T2 - Arhiv za farmaciju T1 - Docking studies of some pyrazole containing compounds in the cyclooxygenase-2 active site T1 - Doking studije nekih jedinjenja sa pirazolom u aktivnom mestu ciklooksigenaze-2 VL - 73 IS - 3 SP - 205 EP - 215 DO - 10.5937/arhfarm73-44720 ER -
@article{ author = "Savić, Jelena and Antonijević, Marija and Crevar, Milkica and Brborić, Jasmina", year = "2023", abstract = "Whereas nonselective nonsteroidal anti-inflammatory drugs, such as aspirin, ibuprofen and diclofenac, inhibit both cyclooxygenase-1 and cyclooxigenase-2 enzymes, selective inhibitors target cyclooxygenase-2, which is overexpressed in inflammation, but also in cancer, atherosclerosis, Alzheimer's disease, and Parkinson`s disease. Potential cardiovascular and hepatic side effects of cyclooxygenase-2 inhibitors have limited their use. The development of selective and safe cyclooxygenase-2 inhibitors remains a high priority in drug discovery. Based on the structure of previously investigated newly synthesized β-hydroxy-β-arylpropanoic acids, two groups of compounds were designed: analogs in which one of the benzene rings was replaced by a pyrazole, while the carboxyl group was retained, and amides of β-hydroxy-β-arylpropanoic acids with pyrazole. The compounds were docked into the 3D structure of the catalytic site of the enzyme cyclooxygenase-2 using AutoDock Vina 1.2.0. and the obtained interactions were compared with the interactions of celecoxib, a selective inhibitor. The amides had lower binding energies than the designed acids, which makes them attractive target compounds for synthesis and further examination., Neselektivni nesteroidni antiinflamatorni lekovi poput aspirina, ibuprofena i diklofenaka inhibiraju enzime ciklooksigenazu-1 i ciklooksigenazu-2, a selektivni inhibitori ciljaju ciklooksigenazu-2 koja je prekomerno izražena u inflamaciji, ali takođe i kod kancera, ateroskleroze, Parkinsonove i Alchajmerove bolesti. Potencijalni kardiovaskularni i hepatički neželjeni efekti selektivnih inhibitora ciklooksigenaze-2 su ograničili njihovu primenu. Razvoj selektivnih i bezbednih inhibitora ciklooksigenaze-2 ostaje veoma prioritetna oblast u otkrivanju lekova. Na osnovu strukture prethodno istraživanih novosintetisanih β-hidroksi-β-arilpropanskih kiselina dizajnirane su dve grupe jedinjenja: analozi u kojima je jedan od benzenovih prstenova zamenjen pirazolom, uz zadržavanje karboksilne grupe, i amidi β-hidroksi-β-arilpropanskih kiselina sa pirazolom. Program AutoDock Vina 1.2.0 je korišćen za dokovanje dizajniranih jedinjenja u 3D strukturu katalitičkog mesta enzima ciklooksigenaze-2, a ostvarene interakcije su upoređene sa interakcijama koje ostvaruje selektivni inhibitor celekoksib. Amidi su imali nižu energiju vezivanja od kiselina, što ih čini dobrim kandidatima za sintezu.", publisher = "Savez farmaceutskih udruženja Srbije (SFUS)", journal = "Arhiv za farmaciju", title = "Docking studies of some pyrazole containing compounds in the cyclooxygenase-2 active site, Doking studije nekih jedinjenja sa pirazolom u aktivnom mestu ciklooksigenaze-2", volume = "73", number = "3", pages = "205-215", doi = "10.5937/arhfarm73-44720" }
Savić, J., Antonijević, M., Crevar, M.,& Brborić, J.. (2023). Docking studies of some pyrazole containing compounds in the cyclooxygenase-2 active site. in Arhiv za farmaciju Savez farmaceutskih udruženja Srbije (SFUS)., 73(3), 205-215. https://doi.org/10.5937/arhfarm73-44720
Savić J, Antonijević M, Crevar M, Brborić J. Docking studies of some pyrazole containing compounds in the cyclooxygenase-2 active site. in Arhiv za farmaciju. 2023;73(3):205-215. doi:10.5937/arhfarm73-44720 .
Savić, Jelena, Antonijević, Marija, Crevar, Milkica, Brborić, Jasmina, "Docking studies of some pyrazole containing compounds in the cyclooxygenase-2 active site" in Arhiv za farmaciju, 73, no. 3 (2023):205-215, https://doi.org/10.5937/arhfarm73-44720 . .